deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT04685564

A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016

A Randomized, Double-blind, Placebo-controlled, Single Dose-escalation, Phase Ia Clinical Study to Evaluate the Safety and Pharmacokinetics of RBD1016 in Healthy Subjects

Sponsor: Suzhou Ribo Life Science Co. Ltd.

Conditions Healthy Volunteers
Interventions Placebo RBD1016
Updated 5 times since 2021 Last updated: Apr 24, 2022 Started: Feb 5, 2021 Primary completion: Sep 8, 2021 Completion: Nov 2, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04685564, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Suzhou Ribo Life Science Co. Ltd., it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~May 2022 · 12 months · monthly snapshotRecruiting~May 2022 – ~Jul 2024 · 26 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. May 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

  4. May 2021 — May 2022 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  5. Jan 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Suzhou Ribo Life Science Co. Ltd.
Data source: Suzhou Ribo Life Science Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations